| Methods |
R = randomised but method not stated
C = not stated
Not blinded |
| Participants |
181 patients randomised
Inclusion criteria according to Chinese stroke diagnosis standards
Ex crit: Intolerance to antiplatelets or anticoagulant drugs, presence of bleeding disorder, low platelet count, cardiac source embolism, infarction induced by tumour, haemorrhagic stroke |
| Interventions |
Aspirin (3 doses: 25 mg, 50 mg, 100 mg) versus ticlopidine 250 mg daily versus lumbrokinase 600 mg |
| Outcomes |
Primary: recurrent stroke |
| Notes |
Co: No information available
Duration of follow up: 12 months
Lost to follow up: 16 patients were not included in the analyses; of these 6 were lost to follow up, 7 suffered brain haemorrhage and 3 had low white cell count; the number in each treatment arm was not available |
